![Michael R. Pavia](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael R. Pavia
Director/Miembro de la Junta en Azevan Pharmaceuticals, Inc. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Neal Gordon Simon | M | - |
Azevan Pharmaceuticals, Inc.
![]() Azevan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem. | 25 años |
Paul J. Maddon | M | 64 |
Azevan Pharmaceuticals, Inc.
![]() Azevan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem. | - |
Geoffrey Smith | M | - |
Azevan Pharmaceuticals, Inc.
![]() Azevan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem. | - |
Michael J. Brownstein | M | - |
Azevan Pharmaceuticals, Inc.
![]() Azevan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem. | - |
Eve M. Damiano | F | - |
Azevan Pharmaceuticals, Inc.
![]() Azevan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem. | - |
Carter Meyer | M | 55 |
Azevan Pharmaceuticals, Inc.
![]() Azevan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem. | - |
Emil Coccaro | M | - |
Azevan Pharmaceuticals, Inc.
![]() Azevan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem. | - |
Ned Heindel | M | - |
Azevan Pharmaceuticals, Inc.
![]() Azevan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem. | - |
Meir Steiner | M | - |
Azevan Pharmaceuticals, Inc.
![]() Azevan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem. | - |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 9 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Michael R. Pavia
- Red Personal